They found a statistically significantly lower achievement rate of low disease activity determined by the DAS28 C-reactive protein in patients with RA positive for anti-Ro/SS-A antibodies, when compared to those negative for anti-Ro/SS-A antibodies, 6 months after MTX treatment [30]. This evidence concerns the gene RO60 and rheumatoid arthritis.